Trial: 201905132

NRG-GY014: A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma

Phase

II

Principal Investigator

Thaker, Premal

Disease Site

Corpus Uteri; Ovary

Learn more about this study at: clinicaltrials.gov